Bloomberg Television · Nov 16, 2026 · 19m · 13m saved
With Brian Moynihan, Chairman and CEO of Bank of America
Photo via fortune.com
Some smaller deals and biotech listings are slipping from this quarter into early 2027, Brian Moynihan, chairman and CEO of Bank of America, told Jonathan Ferro and Lisa Abramowicz on Bloomberg Television's "Bloomberg Surveillance."
The usual reading of a delayed deal is that it may never happen. Brian said these are waiting for the market to digest Anthropic's IPO, and that his bank is still heading for a record year.
"It's not because it won't get done. It's just trying to let the market settle in after this major transaction." — Brian Moynihan
Brian has run Bank of America since 2010. The bank is one of more than 20 working on Anthropic's offering, and its 70 million customers give him a monthly read on what American households spend.
The full segment is covered here so you can skip it. 19 minutes of audio, 6 minutes of reading.
Here are the 8 calls that matter.
Key Takeaways
Deals are delayed, not lost: smaller and biotech listings wait for Anthropic's IPO to clear
Bank of America spent about $300M on AI this year to get about $700M of value
Brian is not worried about founder-controlled AI boards, and compares them to dual-class shares
BofA is beating its own targets early and now guides to 8%-plus interest income growth in 2027
The bank's economists expect three more rate hikes, in December, January and March
Lower-income customers are now increasing their spending faster than higher earners
Brian says 4,000 card competitors already keep card returns in check, against a proposed rate cap
1. Deals Wait on Anthropic
Brian opened on the year in dealmaking. Activity will finish higher, he said, though the path has been uneven.
Brian Moynihan expects capital markets to end 2026 up despite a rough ride
"The capital markets activity, when you all get done with the year, will be up a chunk, but it's been very bumpy." — Brian Moynihan
The deals sliding into early next year are mostly run-of-the-mill offerings and biotech names. Brian said the pause is about timing: investors' attention will go to Anthropic's IPO first. Bank of America is among more than 20 banks on that deal.



